Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
enabled [disable] Abstract
Number of results

Results found: 4

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  chronic obstructive pulmonary disease
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
XX
INTRODUCTION: Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease that develops due to inflammation in the airways. The aim of this study is to demonstrate the effectiveness of c-reactive protein/albumin ratio (CAR) as a 30-day mortality indicator in COPD patients admitted to ICU. MATERIAL AND METHODS: A total of 235 COPD patients with available data between January 2018 and December 2018 were included in this retrospective cohort study. Demographics, APACHE II, Charlson comorbidity index (CCI), SOFA score, CAR and outcomes were evaluated. RESULTS: 87 (37%) of the cases were female and 148 (63%) were male. Their ages ranged from 26 to 95 years, with an average of 70.9± 11.4. The non-survivors had significantly higher APACHE II, CCI, SOFA score, procalcitonin, creatinine, mechanical ventilation (MV) time, WBC, CRP and CAR compared to the survivors (p˂0.05). Albumin and prealbumin were significantly lower (p˂0.05) in non-survivors. In the univariate model; age, sepsis, inotropic support, APACHE II score, CCI, SOFA, procalcitonin, creatinine, MV time, WBC, CRP, albumin, prealbumin and CAR were observed to be significantly effective (p˂0.05) in predicting 30-day mortality. In the multivariate reduced model; inotropic support, SOFA, WBC and prealbumin value exhibited significant independent (p<0.05) effectiveness in predicting 30-day mortality. Albumin, CRP, CAR, APACHE II, SOFA and CCI value were observed to be significant in predicting mortality (p=0.000). CONCLUSIONS: In the study, the predictive power of APACHE II score, CCI, SOFA score, albumin and prealbumin values alone was found to be significantly higher than that of the CAR.
EN
Background To improve the effectiveness of lung cancer screening using low-dose computed tomography (LDCT), the presence of smoking-related comorbidities that may significantly affect mortality in this group should be taken into account. Material and methods A questionnaire survey and spirometry tests were conducted in a group of 730 respondents as part of a lung cancer screening study between 2016 and 2018. People diagnosed with COPD underwent a three-year follow-up to assess the incidence of medical events. Results Our study confirmed that cardiovascular diseases (CVDs) were the most common comorbidities in patients who were diagnosed with COPD and participated in LDCT lung cancer screening. Among the CVDs, the most common were arterial hypertension (45.8%) and coronary artery disease (12.5%). Tobacco-related diseases (e.g. CVD, lung cancer, and exacerbations of COPD) were the leading causes of emergency department visits and hospitalizations. The number of visits due to COPD in specialized clinics more than doubled in the observed period. Conclusions Properly planned screening tests allow not only for the detection of the disease for which they were designed but also for the assessment of comorbidities. In patients undergoing lung cancer screening, it is justified to extend the diagnostics to include spirometry.
EN
Sjögren’s syndrome (SS) is a chronic, systemic, autoimmune inflammatory disease. It is characterized by inflammatory lymphocytic infiltration of exocrine glands, leading to their significant dysfunction and destruction. Lacrimal and salivary glands are commonly affected, causing dryness of the eyes and mouth. The subject of the study is a case report of a 64-year-old woman who had been suffering from discomfort in her right eye for 6 years. Early stage cataract in both eyes, corneal ulceration of the right eye, and a right lower eyelid entropion requiring surgical intervention, were diagnosed at that time. Despite successful treatment, the eyelashes began to grow improperly again and irritated the cornea. Subsequently, the problem of trichiasis also affected the eyelid of the left eye. The eyelashes of both eyes were removed mechanically many times. Sjögren’s syndrome was diagnosed on the basis of the symptoms, a positive Schirmer test and the presence of SS-A antibodies. In the following years, the patient developed keratopathy with corneal epithelial defects, advanced stage cataract, and upper eyelid entropion with associated trichiasis in both eyes. These conditions required both intensive pharmacological and surgical treatment, including an amniotic membrane transplant onto the surface of the right eye, blepharoplasty, lacrimal puncta closure and cataract surgery. Despite the treatment, the patient currently has numerous conjunctival adhesions and vascularized corneal leucoma of the right eye. In addition to the ocular symptoms, the patient has presented other systemic signs.
PL
Zespół Sjögrena (Sjögren’s syndrome – SS) jest przewlekłą, autoimmunologiczną chorobą układową o charakterze zapalnym. Występują w nim limfocytarne nacieki zapalne w gruczołach wydzielania zewnętrznego, co prowadzi do ich znacznej dysfunkcji i zniszczenia. Stan chorobowy najczęściej obejmuje gruczoły łzowe i ślinianki, co powoduje suchość oczu i suchość w jamie ustnej. W pracy opisano przypadek 64-letniej kobiety, która od 6 lat odczuwała dyskomfort w prawym oku. Okulista rozpoznał zaćmę początkową obu oczu, owrzodzenie rogówki oka prawego i podwinięcie powieki dolnej prawej wymagające interwencji chirurgicznej. Pomimo udanego zabiegu rzęsy zaczęły nieprawidłowo odrastać i podrażniać rogówkę. W krótkim czasie problem nieprawidłowo rosnących rzęs objął również powieki lewego oka. Rzęsy powiek obu oczu wielokrotnie usuwano mechanicznie. Na podstawie objawów, dodatniego wyniku testu Schirmera oraz obecności przeciwciał SS-A rozpoznano SS. W kolejnych latach w obu oczach pacjentki rozwinęły się keratopatia wraz z ubytkami na-błonka rogówki, zaawansowana zaćma, podwinięcie górnych powiek oraz związany z tym nieprawidłowy wzrost rzęs. Stany te wymagały intensywnego leczenia farmakologicznego oraz chirurgicznego, w tym naszycia błony owodniowej na powierzchnię oka prawego, plastyki powiek, zamknięcia punktów łzowych i operacji zaćmy. Pomimo leczenia u pacjentki występują obecnie liczne zrosty spojówkowe oraz unaczynione bielmo rogówki prawego oka. Oprócz objawów ocznych pacjentka wykazuje objawy ze strony innych narządów.
EN
Asthma and chronic obstructive pulmonary disease (COPD) are both inflammatory respiratory diseases which links the presence of airflow limitation, that is emphasized in their definition. Underlying inflammation demonstrate a qualitatively difference in the prevailing cells and leading inflammatory mediators in each disease. Response to bronchodilators is also generally different in asthma and COPD. Despite these differences, and significant distinctness of the natural course, prognosis and pathogenesis, in clinical practice a proper diagnosis between these two conditions is often difficult to achieve and may be even impossible in some patients due to overlapping features of asthma and COPD in the same patient. Over the years, some patients with asthma becomes irreversible, and many patients with COPD show significant airway hyperreactivity and partially reversible airflow obstruction. Even the profile of inflammation in severe asthma may change similar to that observed in COPD, and exacerbations of COPD proceed with a greater participation of eosinophils. Common risk factors and the fact that asthma itself can increase the likelihood of developing COPD is considered the main reason of coexistence of both diseases (overlap syndrome). Prevalence of the phenomenon forces to develop effective methods of preventing the emergence overlap syndrome, to better differentiate the both diseases, and to search for optimal management strategies and treatment in the cases of their coexistence.
PL
Astma i przewlekła obturacyjna choroba płuc (POChP) to zapalne choroby dróg oddechowych, które łączy obecność ograniczenia przepływu powierza przez drogi oddechowe podkreślane w ich definicji. Zapalenie, które leży u podłoża obu chorób, różni się jakościowo rodzajem przeważających komórek i głównych mediatorów zapalnych. Inna jest też na ogół odpowiedź na leki rozszerzające oskrzela w astmie i POChP. Pomimo tych różnic i znaczących odrębności naturalnego przebiegu, rokowania i patogenezy właściwe rozpoznanie obu chorób w praktyce jest trudne, a niekiedy nawet niemożliwe z powodu nakładania się cech astmy i POChP u tego samego pacjenta. Wraz z upływem lat u części chorych na astmę dochodzi do utrwalenia się obturacji, a wielu pacjentów z POChP wykazuje istotną reaktywność oskrzeli i częściową odwracalność obturacji. Nawet profil zapalenia w ciężkiej astmie może zmieniać się na podobny do obserwowanego w POChP, a zaostrzenie POChP przebiega niejednokrotnie z większym udziałem eozynofilów. Głównej przyczyny takiego współwystępowania obu schorzeń (zespołu nakładania) upatruje się we wspólnych czynnikach ryzyka i fakcie, że sama astma może zwiększać prawdopodobieństwo wystąpienia POChP. Powszechność zjawiska zmusza do wypracowania skutecznych metod zapobiegania rozwojowi zespołu nakładania, lepszego różnicowania obu chorób, a w przypadku ich współistnienia – do poszukiwania optymalnych sposobów postępowania i leczenia.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.